AustralieFrV1, Main, Exploration, bibRecord, 008406

Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations

Identifieur interne : 008406 ( Main/Exploration ); précédent : 008405; suivant : 008407

Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations

Auteurs : Hanna Jean Khoury [États-Unis] ; Francois Guilhot [France] ; Timothy P. Hughes [Australie] ; Dong-Wook Kim [Corée du Sud] ; Jorge E. Cortes [États-Unis]

Source :

Cancer [ 0008-543X ] ; 2009.

RBID : Pascal:09-0154671

Descripteurs français

Pascal (Inist)
- Dasatinib, Anticancéreux, Traitement, Imatinib, Leucémie myéloïde chronique, Effet secondaire, Protein-tyrosine kinase, Inhibiteur enzyme, Cancérologie, Leucémie Philadelphie positive.

English descriptors

KwdEn :
- Antineoplastic agent, Cancerology, Chronic myelogenous leukemia, Dasatinib, Enzyme inhibitor, Imatinib, Philadelphia-positive leukemia, Protein-tyrosine kinase, Secondary effect, Treatment.

Abstract

Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002E98
to stream PascalFrancis, to step Curation: 003122
to stream PascalFrancis, to step Checkpoint: 002C21
to stream Main, to step Merge: 008B90
to stream Main, to step Curation: 008406

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations</title>
<author><name sortKey="Khoury, Hanna Jean" sort="Khoury, Hanna Jean" uniqKey="Khoury H" first="Hanna Jean" last="Khoury">Hanna Jean Khoury</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Hematology and Medical Oncology, Centre Hospitalier Universitaire</s1>
<s2>Poitiers</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Haematology, Institute of Medical and Veterinary Science</s1>
<s2>Adelaide, South Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Adelaide, South Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Division of Hematology, St. Mary's Hospital, Catholic University of Korea</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Leukemia Department, The University of Texas M. D. Anderson Cancer Center</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0154671</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0154671 INIST</idno>
<idno type="RBID">Pascal:09-0154671</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002E98</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003122</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C21</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002C21</idno>
<idno type="wicri:doubleKey">0008-543X:2009:Khoury H:dasatinib:treatment:for</idno>
<idno type="wicri:Area/Main/Merge">008B90</idno>
<idno type="wicri:Area/Main/Curation">008406</idno>
<idno type="wicri:Area/Main/Exploration">008406</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations</title>
<author><name sortKey="Khoury, Hanna Jean" sort="Khoury, Hanna Jean" uniqKey="Khoury H" first="Hanna Jean" last="Khoury">Hanna Jean Khoury</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Hematology and Medical Oncology, Centre Hospitalier Universitaire</s1>
<s2>Poitiers</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Haematology, Institute of Medical and Veterinary Science</s1>
<s2>Adelaide, South Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Adelaide, South Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Division of Hematology, St. Mary's Hospital, Catholic University of Korea</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Leukemia Department, The University of Texas M. D. Anderson Cancer Center</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer</title>
<title level="j" type="abbreviated">Cancer</title>
<idno type="ISSN">0008-543X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer</title>
<title level="j" type="abbreviated">Cancer</title>
<idno type="ISSN">0008-543X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Chronic myelogenous leukemia</term>
<term>Dasatinib</term>
<term>Enzyme inhibitor</term>
<term>Imatinib</term>
<term>Philadelphia-positive leukemia</term>
<term>Protein-tyrosine kinase</term>
<term>Secondary effect</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dasatinib</term>
<term>Anticancéreux</term>
<term>Traitement</term>
<term>Imatinib</term>
<term>Leucémie myéloïde chronique</term>
<term>Effet secondaire</term>
<term>Protein-tyrosine kinase</term>
<term>Inhibiteur enzyme</term>
<term>Cancérologie</term>
<term>Leucémie Philadelphie positive</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Corée du Sud</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Géorgie (États-Unis)</li>
<li>Nouvelle-Aquitaine</li>
<li>Poitou-Charentes</li>
<li>Région capitale de Séoul</li>
<li>Texas</li>
</region>
<settlement><li>Poitiers</li>
<li>Séoul</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Khoury, Hanna Jean" sort="Khoury, Hanna Jean" uniqKey="Khoury H" first="Hanna Jean" last="Khoury">Hanna Jean Khoury</name>
</region>
<name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
</country>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
</noRegion>
</country>
<country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008406 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008406 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0154671
   |texte=   Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations

Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical Considerations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri